NCT05564650 2026-05-19Navitoclax in Relapsed or Refractory High-Risk Myelodysplastic SyndromeThomas Jefferson UniversityPhase 1 Completed6 enrolled
NCT05455294 2026-01-28Combination Navitoclax, Venetoclax and Decitabine for Advanced Myeloid NeoplasmsDana-Farber Cancer InstitutePhase 1 Active not recruiting16 enrolled